Initiator Pharma completes dosing in Phase 2a pudafensine trial for vulvodynia

• Initiator Pharma completed dosing the last patient in its Phase 2a proof-of-concept study of pudafensine for vulvodynia.
• The randomized, placebo-controlled trial enrolled 24 women to evaluate pain relief and safety.
• Topline results are expected in February 2027.
• Vulvodynia affects approximately 10% of women worldwide, with no medications specifically approved for the condition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Initiator Pharma A/S published the original content used to generate this news brief on October 28, 2026, and is solely responsible for the information contained therein.